<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37270720</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Severe thrombocytopenia is associated with high mortality in systemic lupus erythematosus-analysis from Indian SLE Inception cohort for Research (INSPIRE).</ArticleTitle><Pagination><StartPage>2279</StartPage><EndPage>2285</EndPage><MedlinePgn>2279-2285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06641-5</ELocationID><Abstract><AbstractText>Thrombocytopenia in patients with systemic lupus erythematosus (SLE) is associated with higher morbidity and mortality. We report frequency, associations and short-term outcome of moderate-severe thrombocytopenia in a prospective inception cohort from India (INSPIRE). We evaluated consecutive SLE patients classified per SLICC2012 for the occurrence of thrombocytopenia and its associations. The outcomes assessed included bleeding manifestations, kinetics of thrombocytopenia recovery, mortality and recurrence of thrombocytopenia. Among a total of 2210 patients in the cohort, 230 (10.4%) had incident thrombocytopenia, of whom moderate (platelet count [PC] 20-50&#x2009;&#xd7;&#x2009;10<sup>9</sup>/L) and severe thrombocytopenia (PC&#x2009;&lt;&#x2009;20&#x2009;&#xd7;&#x2009;10<sup>9</sup>/L) were noted in 61 (26.5%) and 22 (9.5%), respectively. Bleeding manifestations were generally limited to the skin. Compared to controls, cases had a higher proportion of autoimmune haemolytic anaemia (p&#x2009;&lt;&#x2009;0.001), leukopenia (p&#x2009;&lt;&#x2009;0.001), lymphopenia (p&#x2009;&lt;&#x2009;0.001), low complement (p&#x2009;&lt;&#x2009;0.05), lupus anticoagulant (p&#x2009;&lt;&#x2009;0.001), higher median SLEDAI 2&#xa0;K (p&#x2009;&lt;&#x2009;0.001) and lower proportion of anti-RNP antibody (p&#x2009;&lt;&#x2009;0.05). There was no significant difference in these variables between moderate and severe thrombocytopenia. There was a sharp rise in PC by 1&#xa0;week that was sustained in the majority through the period of observation. There was three times higher mortality in the severe thrombocytopenia group as compared to moderate thrombocytopenia and controls. The thrombocytopenia relapse and lupus flare rates were similar across categories. We report a low occurrence of major bleeds and higher mortality in those with severe thrombocytopenia as compared to moderate thrombocytopenia and controls. Key Points &#x2022; Severe thrombocytopenia occurs in 1% of patients with SLE; however, major bleeds are uncommon. &#x2022; Thrombocytopenia has a strong association with other lineage cytopenias and lupus anticoagulants. &#x2022; Response to initial glucocorticoids therapy is quick and is well sustained with additional immunosuppressants. &#x2022; Severe thrombocytopenia increases mortality threefold in SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shobha</LastName><ForeName>Vineeta</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5271-0766</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, St. John's Medical College Hospital, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajasekhar</LastName><ForeName>Liza</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-9789-9985</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology &amp; Rheumatology, Nizam Institute of Medical Sciences, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhat</LastName><ForeName>Vasudha</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-6886-5188</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, St. John's Medical College Hospital, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Ashish J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-2061-2042</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology &amp; Rheumatology, Christian Medical College, Vellore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kavadichanda</LastName><ForeName>Chengappa</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3643-3989</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education &amp; Research, Puducherry, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rathi</LastName><ForeName>Manish</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2642-8895</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3965-5410</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selvam</LastName><ForeName>Sumithra</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3229-267X</Identifier><AffiliationInfo><Affiliation>Division of Epidemiology and Biostatistics, St. John's Research Institute, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Amita</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2187-5186</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. aa.amita@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>INSPIRE investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BT/PR23111/MED/30/1852/2017</GrantID><Agency>Department of Biotechnology</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016682">Lupus Coagulation Inhibitor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067251" MajorTopicYN="N">Symptom Flare Up</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013921" MajorTopicYN="Y">Thrombocytopenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007970" MajorTopicYN="Y">Leukopenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016682" MajorTopicYN="N">Lupus Coagulation Inhibitor</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bleeding manifestation</Keyword><Keyword MajorTopicYN="N">Glucocorticoid</Keyword><Keyword MajorTopicYN="N">Immunosuppressants</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">Thrombocytopenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>4</Day><Hour>13</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>4</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37270720</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06641-5</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06641-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78(3):167&#x2013;75. https://doi.org/10.1097/00005792-199905000-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005792-199905000-00003</ArticleId><ArticleId IdType="pubmed">10352648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M (2005) Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 64(9):1366&#x2013;1369. https://doi.org/10.1136/ard.2004.033100</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.033100</ArticleId><ArticleId IdType="pubmed">16100344</ArticleId><ArticleId IdType="pmc">1755663</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL et al (2002) Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 11(3):161&#x2013;167. https://doi.org/10.1191/0961203302lu161oa</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203302lu161oa</ArticleId><ArticleId IdType="pubmed">11999880</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Lee KW, Ho CTK, Lau CS, Wong RWS (2000) A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 39(4):399&#x2013;406. https://doi.org/10.1093/rheumatology/39.4.399</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/39.4.399</ArticleId><ArticleId IdType="pubmed">10817773</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 71(9):1400&#x2013;1412. https://doi.org/10.1002/art.40930</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId><ArticleId IdType="pmc">6827566</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung JH, Soh MS, Ahn YH, Um YJ, Jung JY, Suh CH et al (2016) Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. Medicine (Baltimore) 95(6):e2818. https://doi.org/10.1097/MD.0000000000002818</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000002818</ArticleId><ArticleId IdType="pubmed">26871854</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al (2003) European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82(5):299&#x2013;308. https://doi.org/10.1097/01.md.0000091181.93122.55</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000091181.93122.55</ArticleId><ArticleId IdType="pubmed">14530779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziakas PD, Dafni UG, Giannouli S, Tzioufas AG, Voulgarelis M (2006) Thrombocytopaenia in lupus as a marker of adverse outcome&#x2013;seeking Ariadne&#x2019;s thread. Rheumatology (Oxford) 45(10):1261&#x2013;1265. https://doi.org/10.1093/rheumatology/kel101</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kel101</ArticleId><ArticleId IdType="pubmed">16567353</ArticleId></ArticleIdList></Reference><Reference><Citation>Reveille JD, Bartolucci A, Alarc&#xf3;n GS (1990) Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 33(1):37&#x2013;48. https://doi.org/10.1002/art.1780330105</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780330105</ArticleId><ArticleId IdType="pubmed">2302266</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez M, Alarc&#xf3;n GS, Apte M, Andrade RM, Vil&#xe1; LM, Reveille JD (2007) Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum 56(2):614&#x2013;21. https://doi.org/10.1002/art.22376</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22376</ArticleId><ArticleId IdType="pubmed">17265496</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward MM, Pyun E, Studenski S (1995) Long-term survival in systemic lupus erythematosus Patient characteristics associated with poorer outcomes. Arthritis Rheum. 38(2):274&#x2013;83. https://doi.org/10.1002/art.1780380218</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780380218</ArticleId><ArticleId IdType="pubmed">7848319</ArticleId></ArticleIdList></Reference><Reference><Citation>Shobha V, Aggarwal A, Rajasekhar L, Jain A, Gupta R, Das B et al (2021) Indian SLE Inception cohort for Research (INSPIRE): the design of a multi-institutional cohort. Rheumatol Int 41(5):887&#x2013;894. https://doi.org/10.1007/s00296-020-04766-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04766-3</ArticleId><ArticleId IdType="pubmed">33433731</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf5;n GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677&#x2013;2686. https://doi.org/10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId><ArticleId IdType="pmc">3409311</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB et al (2013) Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood 121(14):2596&#x2013;2606. https://doi.org/10.1182/blood-2012-07-442392</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-07-442392</ArticleId><ArticleId IdType="pubmed">23361904</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN et al (2019) 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736&#x2013;745. https://doi.org/10.1136/annrheumdis-2019-215089</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 142(12 Pt 1):953&#x2013;962. https://doi.org/10.7326/0003-4819-142-12_part_1-200506210-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-142-12_part_1-200506210-00004</ArticleId><ArticleId IdType="pubmed">15968009</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Zhang W, Leng X, Li Z, Ye Z, Li C et al (2013) Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus 22(11):1192&#x2013;9. https://doi.org/10.1177/0961203313499086</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313499086</ArticleId><ArticleId IdType="pubmed">23963101</ArticleId></ArticleIdList></Reference><Reference><Citation>Skare T, Damin R, Hofius R (2015) Prevalence of the American College of Rheumatology hematological classification criteria and associations with serological and clinical variables in 460 systemic lupus erythematosus patients. Rev Bras Hematol Hemoter 37(2):115&#x2013;119. https://doi.org/10.1016/j.bjhh.2015.01.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjhh.2015.01.006</ArticleId><ArticleId IdType="pubmed">25818822</ArticleId><ArticleId IdType="pmc">4382578</ArticleId></ArticleIdList></Reference><Reference><Citation>Chock YP, Moulinet T, Dufrost V, Erkan D, Wahl D, Zuily S (2019) Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 18(11):102395. https://doi.org/10.1016/j.autrev.2019.102395</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.102395</ArticleId><ArticleId IdType="pubmed">31520800</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnal C, Piette J, L&#xe9;one J, Taillan B, Hachulla E, Roudot-Thoraval F et al (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29(1):75&#x2013;83</Citation><ArticleIdList><ArticleId IdType="pubmed">11824975</ArticleId></ArticleIdList></Reference><Reference><Citation>Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR (1991) Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21(1):55&#x2013;64. https://doi.org/10.1016/0049-0172(91)90057-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-0172(91)90057-7</ArticleId><ArticleId IdType="pubmed">1948102</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>